Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat
Science Translational Medicine · 2026
DOI: 10.1126/scitranslmed.aea3115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Gerhard Jungwirth und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Neurosurgery, Department of Neurosurgery, Heidelberg University, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Panobinostat, Organoids, Meningioma, Histone Deacetylase 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Else Kröner-Fresenius-Stiftung, China Scholarship Council, Deutsche Krebshilfe.
Abstract (Originalsprache)
Managing aggressive meningiomas remains challenging because of limited treatment options besides surgical tumor removal and radiotherapy. To increase the repertoire of promising therapies for aggressive meningiomas, we established a multistep drug screening workflow, focusing on targetable genes obtained from transcriptome data of highly aggressive grade 3 meningiomas. In vitro screening of 107 targeted drugs identified nine effective inhibitors. To study these drugs in a more natural environment, we established a standardized patient-derived tumor organoid (TO) model preserving accurately the original tissue’s genotype and phenotype. Individual drug responses were assessed in TOs from 60 meningioma cases characterized at the molecular level. In particular, the US Food and Drug Administration–approved epigenetic drug panobinostat demonstrated high antimeningioma efficacy in 70% of TOs, mediated through histone deacetylase 1 and 2 (HDAC1/2) inhibition. In addition, treatment in an orthotopic in vivo model revealed improved survival. In search of the molecular mechanism underlying a potentially intrinsic panobinostat resistance, we identified up-regulation of the HDAC8–transforming growth factor–β (TGFβ)–epithelial-to-mesenchymal transition (EMT) axis in the TO model, whereas subsequent HDAC8 depletion increased the sensitivity to panobinostat. These data highlight the utility of personalized drug screenings on TOs to identify suitable drug targets and inhibitors for more effective treatment of clinically aggressive meningiomas and to help advance our understanding of counteracting resistance mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Experimental Neurosurgery, Department of Neurosurgery, Heidelberg University, 69120 Heidelberg, Germany.
- German Cancer Consortium (DKTK) Core-Center Heidelberg, Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Division of Molecular and Translational Radiation Oncology, Heidelberg Faculty of Medicine (MFHD), Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), 69120 Heidelberg, Germany.
- Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Department of Clinical Pathology, Suez Canal University, 41522 Ismailia, Egypt.
- Department of Radiation Oncology and Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg University Hospital (UKHD), 69120 Heidelberg, Germany.
ORCID-Profile: Gerhard Jungwirth, Junguo Cao, Rolf Warta, Catharina Lotsch, Mahmoud Moustafa, Maximilian Knoll, Tao Yu, Viktor Braun, Lena Jassowicz, Philip Dao Trong, Alexander Younsi, Moritz Scherer, Martin Bendszus, Sandro M Krieg, Andreas von Deimling, Juergen Debus, Amir Abdollahi, Felix Sahm, Christel Herold-Mende
Förderung
- Else Kröner-Fresenius-Stiftung
- China Scholarship Council
- Deutsche Krebshilfe
- Else Kr ner Fresenius Stiftung
- Medical Faculty of Heidelberg
- Physician Scientist Program of the Heidelberg Faculty of Medicine
Zitieren
APA
Jungwirth, G., Cao, J., Pan, Y., Warta, R., Lotsch, C., Moustafa, M., Knoll, M., Yu, T., Braun, V., Jassowicz, L., Trong, P. D., Wang, Z., Younsi, A., Scherer, M., Bendszus, M., Krieg, S. M., von Deimling, A., Debus, J., Abdollahi, A., …, & Herold-Mende, C. (2026). Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aea3115
Vancouver
Jungwirth G, Cao J, Pan Y, Warta R, Lotsch C, Moustafa M, et al. Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aea3115
BibTeX
@article{Jungwirth2026,
author = {Jungwirth, Gerhard and Cao, Junguo and Pan, Yimin and Warta, Rolf and Lotsch, Catharina and Moustafa, Mahmoud and Knoll, Maximilian and Yu, Tao and Braun, Viktor and Jassowicz, Lena and Trong, Philip Dao and Wang, Zhenlin and Younsi, Alexander and Scherer, Moritz and Bendszus, Martin and Krieg, Sandro M and von Deimling, Andreas and Debus, Juergen and Abdollahi, Amir and Unterberg, Andreas and Sahm, Felix and Herold-Mende, Christel},
title = {Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat},
journal = {Science Translational Medicine},
year = {2026},
doi = {10.1126/scitranslmed.aea3115}
}
EUVIMED